Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rang in aandelen #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Aandeelprijs
$0.5275
Marktkapitalisatie
$1.25M
Verandering (1 dag)
-3.56%
Verandering (1 jaar)
-83.77%
Land
US
Handel Ensysce Biosciences, Inc. (ENSC)

Categorie

Healthcare
P/B-ratio voor Ensysce Biosciences, Inc. (ENSC)
P/B-ratio op March 2026 TTM: 0.98
Volgens de meest recente financiële rapporten en aandelenkoers van Ensysce Biosciences, Inc. is de huidige P/B-ratio (TTM) 0.98. Eind 2023 had het bedrijf een P/B-ratio van -111.50.
P/B-ratiohistoriek voor Ensysce Biosciences, Inc. van 2017 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) 0.98 -74.51%
2024 3.83 -103.44%
2023 -111.50 1,749.65%
2022 -6.03 -96.66%
2021 -180.44 -99.42%
2020 -30.98K -2,624.64%
2019 1.23K 14.10%
2018 1.08K 2.10%
2017 1.05K 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 479.58%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 554.05%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 151.52%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 347.09%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5504 161.28%
AU